Will integrase inhibitors be used as microbicides?

Current HIV Research

Volumn 10, Issue 1, 2012, Pages 36-41

  Crucitti, Giuliana C ^a   Botta, Maurizio ^b   Di Santo, Roberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Aryl diketo acids; HIV; Integrase inhibitor; Microbicide; Naphthyridinecarboxamide

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DAPIVIRINE; ENFUVIRTIDE; INTEGRASE; INTEGRASE INHIBITOR; L 731 988; L 870812; MICROBICIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; OXOACID; RALTEGRAVIR; RDS 1624; RDS 1625; RDS 1996; RDS 1997; RDS 2196; RDS 2197; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENZYME; VIRUS RNA; ZIDOVUDINE;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHEMOPROPHYLAXIS; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; SEXUALLY TRANSMITTED DISEASE; VIRUS INHIBITION;

ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS, LOCAL; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS;

EID: 84857133549     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212799304706     Document Type: Article

References (47)

1. http://www.who.int/hiv/data/en/.
2. Moscicki AB. Vaginal microbicides: where are we and where are we going. J Infected Chemother 2008; 14: 337-341.
3. Nuttall J, Romano J, Douville K, et al. The future of HIV prevention: prospects for an effective anti-HIV microbicide. Infect Dis Clin N Am 2007; 21: 219-239.
4. Hillier SL, Moench R, Shattock R, et al. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune DeficSyndr 2005; 39: 1-8.
5. Tevi-Benissan C, Makuva M, Morelli A, et al. Protection of cynomolgus macaque against cervicovaginaltrasmission of SIVmac251 by the spermicide benzalkonium chloride. J Acquir Immune DeficSyndr 2000; 24: 147-153.
6. Scordi-Bello IA, Mosoian A, He Y, et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanism of action. Antimicrob Agents Chemother 2005; 49: 3607-3615.
7. Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of current vulvovaginal candidiasis: a review. J AntimicrobChemother 2006; 58: 266-272.
8. Balzarini J, Van Damme L. Microbicides drug candidates to prevent HIV infection. Lancet 2007; 369: 787-797.
9. Jenabian MA, Saïdi H, Charpentier C, et al. In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). J AntimicrobChemother 2009; 64: 1192-1195.
10. Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 2008; 51: 5843-5855.
11. Costi R, Di Santo R, Artico M, et al. 6-Aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays. Bioorg Med ChemLett 2004; 14: 1745-1749.
12. Engelman A, Bushman FD, Craigie R. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO Journal 1993; 12: 3269-3275.
13. Hare S, Gupta SS, Valkon E. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010; 464: 232-237.
14. Dyda F, Hickman A, Jenkins T. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotide transferases. Science 1994; 266: 1981-1986.
15. Gao K, Gorelick R, Johnson D, Bushman F. Cofactors for HIV-1 cDNA integration in vitro. J Virol 2003; 77: 1598-1603.
16. Bukrinsky M, Sharova N, McDonald T. Association of integrase, matrix, and reverse transcriptase antigens of HIV-1 with viral nucleic acids following acute infection. ProcNatlAcadSci U.S.A. 1993; 90: 6125-6129.
17. Tramontano E, Onidi L, Esposito F, et al. The use of a new in vitro reaction substrate reproducing both U3 and U5 regions of the HIV-1 3'-end increases the correlation between the in vitro and in vivo effects of the HIV-1 integrase inhibitors. Biochem Pharmacol 2004; 67: 1751-1761.
18. Hong-qiu H, Xiao-hui M, Bin L, et al. High-throughput real-time assay based on molecular beacons for HIV-1 integrase 3'-processing reaction. ActaPharmacol Sin 2007; 28: 811-817.
19. Pendri A, Meanwell NA, Peese KM, Walke M. New first and second generation inhibitors of human immunodeficiency virus-1 integrase. Expert OpinTher Pat 2011; 21: 1173-1189.
20. Hayouka Z, Levin A, Maes M, et al. Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370. Biochem Biophys Research Comm 2010; 394: 260-265.
21. Fan X, Zhang FH, Al-Safi RI, et al. Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: A scaffold hopping approach using salicylate and catechol groups. Bioorg Med Chem 2011; 19: 4935-4952.
22. Farnet CM, Wang B, Russell Lipford J, Bushman FD. Differential inhibition of HIV-1 preintegrationcomplexs and purified integrase protein by small molecules. ProcNatlAcadSci U.S.A. 1996; 93: 9742-9747.
23. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitors raltegravir (MK-0518) in treatmentexperienced patients with multidrug-resistant virus: A phase II randomised controlled trials. Lancet2007; 369: 1261-1269.
24. Sato M, Kawakami H, Motomura T, et al. Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors. J Med Chem 2009; 13: 4869-4882.
25. Hare S, Smith SJ, Metifiot M, et al. Structural and Functional Analyses of the Second-generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572). MolPharmacol 2011; Jun 30.
26. http://www.who.int/hiv/topics/microbicides/microbicides/en/.
27. van de Wijgert JH, Shattock RJ. Vaginal microbicides: moving ahead after an unexpected setback. Aids 2007; 21: 2369-2376.
28. http://clinicaltrials.gov/ct2/results?term=dapivirine.
29. Abdool KQ, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gels, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010: 329: 1168-1174.
30. Terrazas-Aranda K, Van Herrewege Y, Hazuda D, et al. Human immunodeficiency virus type 1 (HIV-1) integration: a potential terget for microbicidesto prevent cell-free and cell-associated HIV-1 infection. Antimicrob Agents Chemother 2008; 52: 2544-2554.
31. McElrath MJ, Ballweber L, Terker A, et al. Ex vivo comparisons of microbicides efficacies for preventing HIV-1 genomic integration in intraephitelial vaginal cell. Antimicrob Agents Chemother 2010; 54: 763-772.
32. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003; 17: 455-480.
33. Hladik F, Sakchalathorn P, Ballweber L, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26: 257-270.
34. Van Herrewege Y, Michiels J, Van Roey J, et al. Activity of reverse transcriptase inhibitors in monocyte derived dendritic cells: a possible model for post exposure prophylaxis of sexual HIV transmission. AIDS Res Hum Retrovr 2002; 18: 1091-1102.
35. Terrazas-Aranda K, Van Herrewege Y, Lewi PJ, Van Roey J, Vanham G. In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection. AntivirChemChemother 2007; 18: 141-151.
36. Di Santo R, Costi R, Roux A, et al. Novel bifunctionalquinolonyldiketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action. J Med Chem2006; 49: 1939-1945.
37. Di Santo R, Costi R, Roux A, et al. Novel quinolonyldiketo acids derivatives as HIVintegrase inhibitors: design, synthesis and biological activities. J Med Chem 2008; 51: 4744-4750.
38. Hzuda DJ, Felow P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cell. Science 2000; 247: 646-650.
39. De Clerck E. Emerging anti HIV-1 drugs. Expert Opin Emerge Drugs 2005; 10: 241-273.
40. Kilby JM, Eron JJ. Novel therapies based on machanism of HIV-1 entry. N Engl J Med 2003; 348: 2228-2238.
41. Cihlar T; Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res 2010; 85: 39-58.
42. De Clercq E. Clinical potential of the acyclic nucleoside phosphonatescidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16: 569-596.
43. Clark MR, McCormick TJ, Doncel GF, et al. Preclinical evaluation of UC781 microbicide vaginal drug delivery. Drug Deliv Transl Res 2011; 1: 175-182.
44. Nel AM, Coplan P, van de Wijgert JH, et al. Safety, tolerability, and systemic absorption of dapivirinevaginal microbicide gel in healthy, HIV-negative women. AIDS (London, England) 2009; 23: 1531-1538.
45. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, non peptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U.S.A. 1999; 96: 5698-5703.
46. Zhang X, Pais GCG, Svarovskaia ES, et al. Azido-containing aryl diketo acid HIV-1 integrase inhibitors. Bioorg Med ChemLett 2003; 13: 1215-1219.
47. Hladik F, Sakchalathorn P, Ballweber L, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26: 257-270.